SCHEMBL7147864

SCHEMBL7147864

CCCCOc1nc(N)nc(-c2ccco2)c1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 2/20 0.45
ALDH1A1 P00352 2/20 0.45
TP53 P04637 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
TSHR P16473 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HSD17B10 Q99714 2/20 0.45
ADORA2A P29274 13/20 0.44
ADORA1 P30542 7/20 0.43
HDAC1 Q13547 2/20 0.43
CCNA2 P20248 2/20 0.40
CDK2 P24941 2/20 0.40
CCNA1 P78396 2/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
PIN1 Q13526 1/20 0.40
CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7147047 0.88 ADORA2A (0.47) KDM4ENPC1ALDH1A1TP53MAPT
SCHEMBL7151592 0.88 ADORA2A (0.44) ADORA2AADORA1HDAC1DHFR
SCHEMBL7146875 0.85 ADORA2A (0.43) ADORA2AADORA1HDAC1CCNA2CDK2
SCHEMBL5046627 0.84 ADORA2A (0.53) ADORA2AADORA1HDAC1
SCHEMBL7149986 0.83 ADORA2A (0.51) SMN1; SMN2ADORA2AADORA1CCNA2CDK2
SCHEMBL6441743 0.82 ADORA1 (0.56) KDM4ENPC1ALDH1A1TP53MAPT
SCHEMBL7152758 0.80 ADORA2A (0.51) MAPTADORA2AADORA1
SCHEMBL7144843 0.80 ADORA2A (0.49) TSHRADORA2AADORA1CCNA2CDK2
SCHEMBL7169211 0.78 ADORA2A (0.45) NPC1ALDH1A1TSHRRAB9AADORA2A
SCHEMBL1553903 0.78 ADORA2A (0.60) KDM4EALDH1A1MAPTHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 KDM4E 3250/4885NPC1 2213/4885ALDH1A1 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.